Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.93
VSCP's Cash to Debt is ranked higher than
56% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 2.75 vs. VSCP: 4.93 )
Ranked among companies with meaningful Cash to Debt only.
VSCP' s Cash to Debt Range Over the Past 10 Years
Min: 4.93  Med: 10000.00 Max: No Debt
Current: 4.93
Equity to Asset 0.59
VSCP's Equity to Asset is ranked lower than
59% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. VSCP: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
VSCP' s Equity to Asset Range Over the Past 10 Years
Min: -0.97  Med: 0.74 Max: 0.88
Current: 0.59
-0.97
0.88
F-Score: 3
Z-Score: -0.65
M-Score: -1.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -18.59
VSCP's Operating margin (%) is ranked lower than
65% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. VSCP: -18.59 )
Ranked among companies with meaningful Operating margin (%) only.
VSCP' s Operating margin (%) Range Over the Past 10 Years
Min: -95.59  Med: -28.75 Max: 6.51
Current: -18.59
-95.59
6.51
Net-margin (%) -18.82
VSCP's Net-margin (%) is ranked lower than
65% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. VSCP: -18.82 )
Ranked among companies with meaningful Net-margin (%) only.
VSCP' s Net-margin (%) Range Over the Past 10 Years
Min: -98.53  Med: -28.66 Max: 4.92
Current: -18.82
-98.53
4.92
ROE (%) -52.86
VSCP's ROE (%) is ranked lower than
79% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. VSCP: -52.86 )
Ranked among companies with meaningful ROE (%) only.
VSCP' s ROE (%) Range Over the Past 10 Years
Min: -120.47  Med: -35.94 Max: 9.72
Current: -52.86
-120.47
9.72
ROA (%) -30.82
VSCP's ROA (%) is ranked lower than
74% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.42 vs. VSCP: -30.82 )
Ranked among companies with meaningful ROA (%) only.
VSCP' s ROA (%) Range Over the Past 10 Years
Min: -95.8  Med: -23.25 Max: 6.9
Current: -30.82
-95.8
6.9
ROC (Joel Greenblatt) (%) -308.31
VSCP's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. VSCP: -308.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VSCP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1378.21  Med: -454.87 Max: 202.79
Current: -308.31
-1378.21
202.79
Revenue Growth (3Y)(%) -6.50
VSCP's Revenue Growth (3Y)(%) is ranked lower than
77% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. VSCP: -6.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VSCP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.9  Med: 11.90 Max: 573.1
Current: -6.5
-9.9
573.1
» VSCP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

VSCP Guru Trades in Q4 2014

Jim Simons 15,890 sh (+11.20%)
» More
Q1 2015

VSCP Guru Trades in Q1 2015

Jim Simons 16,090 sh (+1.26%)
» More
Q2 2015

VSCP Guru Trades in Q2 2015

Jim Simons 16,090 sh (unchged)
» More
Q3 2015

VSCP Guru Trades in Q3 2015

Jim Simons 17,590 sh (+9.32%)
» More
» Details

Insider Trades

Latest Guru Trades with VSCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.15
VSCP's P/B is ranked lower than
60% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. VSCP: 3.15 )
Ranked among companies with meaningful P/B only.
VSCP' s P/B Range Over the Past 10 Years
Min: 1  Med: 3.37 Max: 19.94
Current: 3.15
1
19.94
P/S 0.97
VSCP's P/S is ranked higher than
79% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. VSCP: 0.97 )
Ranked among companies with meaningful P/S only.
VSCP' s P/S Range Over the Past 10 Years
Min: 0.47  Med: 2.40 Max: 85.05
Current: 0.97
0.47
85.05
Current Ratio 2.02
VSCP's Current Ratio is ranked lower than
64% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.82 vs. VSCP: 2.02 )
Ranked among companies with meaningful Current Ratio only.
VSCP' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.16 Max: 6.97
Current: 2.02
0.03
6.97
Quick Ratio 2.02
VSCP's Quick Ratio is ranked higher than
50% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. VSCP: 2.02 )
Ranked among companies with meaningful Quick Ratio only.
VSCP' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 3.16 Max: 6.97
Current: 2.02
0.03
6.97
Days Sales Outstanding 79.04
VSCP's Days Sales Outstanding is ranked lower than
61% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 69.24 vs. VSCP: 79.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
VSCP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.88  Med: 52.26 Max: 74.35
Current: 79.04
41.88
74.35

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 5.39
VSCP's Price/Net Current Asset Value is ranked higher than
56% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 6.17 vs. VSCP: 5.39 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VSCP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.35  Med: 4.83 Max: 29.5
Current: 5.39
1.35
29.5
Price/Tangible Book 4.30
VSCP's Price/Tangible Book is ranked higher than
50% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. VSCP: 4.30 )
Ranked among companies with meaningful Price/Tangible Book only.
VSCP' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.31  Med: 4.42 Max: 23.79
Current: 4.3
1.31
23.79
Price/Median PS Value 0.41
VSCP's Price/Median PS Value is ranked higher than
90% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. VSCP: 0.41 )
Ranked among companies with meaningful Price/Median PS Value only.
VSCP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.95 Max: 35.5
Current: 0.41
0.21
35.5
Earnings Yield (Greenblatt) (%) -21.60
VSCP's Earnings Yield (Greenblatt) (%) is ranked lower than
88% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. VSCP: -21.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VSCP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -21.96  Med: 1.40 Max: 3
Current: -21.6
-21.96
3

More Statistics

Revenue(Mil) $12
EPS $ -0.80
Beta3.76
Short Percentage of Float1.76%
52-Week Range $1.73 - 6.65
Shares Outstanding(Mil)3.00

Analyst Estimate

Dec15
Revenue(Mil)
EPS($) -0.60
EPS without NRI($) -0.60

Business Description

Industry: Medical Devices » Medical Devices
Compare:PAYX, AHEXY, RANJY, TMH, HAYPY » details
VirtualScopics Inc. is a provider of quantitative imaging for clinical trials serving the pharmaceutical, biotechnology and medical device industries. The Company has developed a software platform for analysis and modeling of both structural and functional medical images. This platform provides information about the biological activity of drugs and devices in clinical trial patients. VirtualScopics is an imaging core lab providing central reads and quantitative imaging solutions for drug and medical device clinical trials for the areas of oncology, rheumatoid arthritis, osteoarthritis, neurology, and cardiovascular studies utilizing MRI, PET, CT, Ultrasound, and X-ray imaging modalities. The Company's image-based measurement and visualization tools enable automated and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological and neurological diseases. The Company's image analysis provides a degree of accuracy and reproducibility that cannot be duplicated by manual techniques. The Company's quantitative imaging replaces subjective evaluation. It has developed a suite of patented semi-automated tools for the identification and measurement of carotid plaques. Evaluating diseases such as multiple sclerosis (MS), epilepsy, and Alzheimer's requires the identification and measurement of neurological structures and lesions. The Company's competition is largely comprised of a limited number of university research centers that are working on developing the next generation of image analysis tools. The Company's main customers are Novartis, Merck Serono and Amgen. The Company's main competitors are clinical research organizations (CROs) providing clinical trial services to pharmaceutical companies. Healthcare in the United States is heavily regulated by the federal government, and by state and local governments.
» More Articles for VSCP

Headlines

Articles On GuruFocus.com

More From Other Websites
VIRTUALSCOPICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Jan 22 2016
VirtualScopics, Inc. Announces Amendment to Exclusive Marketing Agreement with PPD; Provides... Jan 22 2016
VirtualScopics, Inc. Announces Amendment to Exclusive Marketing Agreement with PPD; Provides... Jan 22 2016
Edited Transcript of VSCP earnings conference call or presentation 29-Oct-15 8:30pm GMT Jan 06 2016
VIRTUALSCOPICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 21 2015
VirtualScopics, Inc. Promotes Ronald Way to Chief Operating Officer Dec 17 2015
VirtualScopics, Inc. Promotes Ronald Way to Chief Operating Officer Dec 17 2015
VIRTUALSCOPICS, INC. Financials Dec 08 2015
VIRTUALSCOPICS, INC. Files SEC form 10-Q, Quarterly Report Nov 13 2015
VIRTUALSCOPICS, INC. Files SEC form 8-K, Regulation FD Disclosure Nov 03 2015
Why Are These Four Stocks Surging on Monday? Nov 02 2015
VIRTUALSCOPICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Oct 29 2015
VirtualScopics, Inc. Reports 2015 Third Quarter Revenues Increase 18% From Prior Year Period And... Oct 29 2015
VirtualScopics, Inc. Reports 2015 Third Quarter Revenues Increase 18% From Prior Year Period And... Oct 29 2015
VirtualScopics, Inc. to Host Third Quarter 2015 Earnings Conference Call and Webcast Live on... Oct 28 2015
VirtualScopics, Inc. Schedules Third Quarter 2015 Financial Results Press Release, Conference Call... Oct 14 2015
VirtualScopics, Inc. Schedules Third Quarter 2015 Financial Results Press Release, Conference Call... Oct 14 2015
VirtualScopics, Inc. Earnings Q2, 2015 Sep 30 2015
VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology... Sep 03 2015
VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology... Sep 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK